Release Date: December 10, 2022
Expiration Date: January 2, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward hematologists, medical oncologists, specialty pharmacists, researchers and investigators who treat or are interested in the prevention and treatment of transplant-related CMV infection. Other allied healthcare professionals involved in prevention and management of transplant-related CMV infection will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify risk factors for CMV and assess the impact of CMV on treatment outcomes for patients who undergo HSCT
- Outline current and emerging strategies for primary and secondary prevention of CMV infection in patients undergoing HSCT
- Devise strategies to integrate evidence-based data and expert recommendations into current clinical practice to prevent and treat CMV infection post-HSCT
- Discuss mechanisms that lead to development of resistant CMV infection as well as current and emerging strategies to address CMV infections resistant or refractory to current antiviral therapies in patients who undergo HSCT
Genovefa Papanicolaou, MD
Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Merck&Co (MSD); Consultant: MSD, Takeda, Behring SLC, Cidara; Other: Allovir (DSMC member), Octapharma (EAC member).
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
The University of Texas School of Public Health
Professor, Department of Infectious Diseases, Infection Control & Employee Health
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Merck, Takeda, AiCuris, Ansun, Viracor, Karius, Genentech, Freestyle; Consultant: ADMA Biologics, Merck, Karius, Ansun, Viracor, Qiagen, Aseptico, Shinoigi, Janssen, Molecular Partners, Oxford Immunotec, AiCuris; Shareholder: Xenex (Stock Options).
Sanjeet Dadwal, MD, FACP, FIDSA
Professor & Chief, Division of Infectious Disease
City of Hope National Medical Center
Duarte, CA
Disclosures: Grant/Research Support: Allovir, Takeda/Shire, Gilead, Ansun Biopharma, Amplyx/Pfizer; Consultant: Allovir, Merck; Speakers’ Bureau: Astellas, Merck; Shareholder: Aseptiscope; Advisory board: Aseptiscope, Merck, Cidara.
Guenther Koehne, MD, PhD
Deputy Director and Chief
Blood & Marrow Transplant, Hematologic Oncology and Benign Hematology
Miami Cancer Institute
Miami, FL
Guenther Koehne, MD, PhD has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
